Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
This article was originally published in PharmAsia News
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year
You may also be interested in...
Johnson & Johnson may soon face more competition to Remicade from Celltrion’s biosimilar Remsima, with the South Korean company more optimistic about EMA approval following a positive response at one of the world’s largest rheumatology congresses.
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.
Celltrion says it will launch Phase III trials in the second half of 2013 with a new design, after completing a Phase I trial this month.